Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

February 16, 2023

Study Completion Date

September 30, 2026

Conditions
Type1 Diabetes
Interventions
DRUG

Aldesleukin

"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"

OTHER

Placebo

sterile diluent used for the aldesleukin preparation and 5% glucose

Trial Locations (5)

OX3 9DU

Oxford Children's Hospital, Oxford

Unknown

Bristol Royal Hospital for Children, Bristol

Addenbrooke's Hospital, Cambridge

The Great North Children's Hospital, Newcastle upon Tyne

Nottingham Children's Hospital, Nottingham

Sponsors
All Listed Sponsors
collaborator

Oxford Clinical Trials Research Unit (OCTRU)

UNKNOWN

collaborator

Centre for Statistics in Medicine, Oxford

UNKNOWN

collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

Wellcome Trust

OTHER

lead

University of Oxford

OTHER